Contact us

Clinical support

Supporting healthcare professionals

More than just reliably delivering nutritional products that help address the complications of prematurity, we’re also your clinical partner. This is why we’re always working to advance the understanding and add to the growing body of clinical evidence around human milk. We’re here with medical, clinical, economic, and research support.

Getting the most out of an EHMD

Address comorbidities

Understand the evidence behind the reductions in bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), late-onset sepsis, and necrotizing enterocolitis (NEC)

Clinical value

Learn about cost savings, complication reductions, and health outcomes associated with the use of our human milk–based nutritional products

Clinical resources

Get guidance and see how other hospitals are leveraging an EHMD

Talk to our clinical experts

Nutrition Advisory Committee (NAC)

We’re a group of leading registered dietitians who are passionate about human milk science and nutrition. After witnessing firsthand the improved patient outcomes of an Exclusive Human Milk Diet (EHMD) with neonatal patients, our mission is to enhance clinical practice, education, and outcomes in the neonatal intensive care unit (NICU) by sharing clinical expertise and emerging research.

Email: NAC@prolacta.com

Nursing Practice Advisory Council (NPAC)

As neonatal nurses and nurse practitioners, we have extensive clinical experience with mother’s own milk, donor milk, and human milk–based products. We’re available to help you enhance clinical practice, education, and outcomes in your NICU by sharing our clinical expertise in the use of an EHMD.

Email: NPAC@prolacta.com

Safely helping premature infants grow

A growing body of clinical evidence supports the use of an EHMD, including Prolacta’s 100% human milk–based fortifiers, as a new standard of care for premature infants born at ≤1250 g1,2,3,4. Enhanced protocols with earlier fortification using Prolacta’s fortifiers have been associated with improved growth5,6, optimized lung health2,3, a lower risk of complications7,8,9, reduced healthcare costs1,10, and shorter NICU stays1 for infants receiving an EHMD.

This latest study by lead author Robert Huston, MD, published in the Journal of Neonatal-Perinatal Medicine, found that fortification with Prolacta’s 100% human milk–based fortifiers in the first days of life improves growth and reduces the risk of BPD by 15% for infants receiving an EHMD, without the increased risk of complications seen with cow milk–based fortifiers.

The Huston et al early fortification study provides further data to support the practice of fortifying the human milk feedings of infants born at ≤1250 g birth weight with a 100% human milk–based fortifier at a lower feeding volume (≤60 mL/kg/day) than has been a standard feeding practice in the past.

Tell us how we can help

Clinician-to-clinician guidance

Coding, billing, and reimbursement questions

Finding my sales representative

Support with and order

Citations